Neuraxpharm Pharmaceuticals S.L.

Address: Avinguda De Barcelona 69

Sponsor Overview

assignment

Specializations

Multiple Sclerosis and fumarate therapies

Clinical research includes multiple sclerosis with attention to oral disease-modifying therapy and gastrointestinal tolerability in healthy volunteers. The sponsor’s portfolio in this area reflects interest in dimethyl fumarate and related fumarate-based treatments.

Multiple sclerosis
Dimethyl fumarate
Gastrointestinal tolerability
Oral disease-modifying therapy

These studies focus on treatment-related tolerability and comparative assessment of oral therapies used in neurological disease.

Epilepsy and focal onset seizures

The sponsor is active in refractory partial onset epilepsy, with research centered on focal onset seizures and the clinical performance of levetiracetam formulations. This area links seizure control with extended-release treatment options.

Refractory partial onset epilepsy
Focal onset seizures
Levetiracetam extended release
Drug-resistant epilepsy

Research in this field addresses seizure frequency reduction and the use of antiepileptic therapy in patients with difficult-to-control epilepsy.

Bioequivalence and comparative bioavailability

A substantial part of the research portfolio involves bioequivalence and comparative bioavailability studies in healthy subjects. These trials evaluate oral formulations intended to match established reference products in systemic exposure.

Bioequivalence
Comparative bioavailability
Healthy subjects
Oral formulations

Examples include studies of oxazepam orodispersible tablets and other formulation comparisons relevant to central nervous system medicines.

Midazolam formulation comparison

The sponsor also supports research on midazolam in different administration routes, including oromucosal and intramuscular formulations. The focus is on pharmacokinetic comparison in healthy volunteers.

Midazolam
Oromucosal solution
Intramuscular injection
Pharmacokinetics

This area is relevant to the clinical use of benzodiazepines and formulation selection for rapid therapeutic delivery.

Central nervous system medicines

Across its funded studies, the sponsor shows interest in therapies for the central nervous system, including anxiolytic, antiepileptic, and neurological treatments. The research portfolio spans both established medicines and alternative dosage forms.

Central nervous system medicines
Benzodiazepines
Antiepileptic treatments
Neurological disorders

The clinical landscape includes formulation-focused work alongside studies in neurology and seizure-related conditions.

Trial Name	Country	Status
Bioavailability Comparison of Midazolam Oromucosal Solution Versus Solution for Injection in Healthy Subjects	Portugal	Not Recruiting
Comparative Bioavailability and Bioequivalence of Oxazepam 10 mg Orodispersible Tablets (Test) Versus Seresta® 10 mg Tablets (Reference): A Single-Dose, Open-Label, Randomized, Two-Sequence, Two-Treatment, Two-Period Crossover Study in Healthy Subjects	Portugal	Not Recruiting
Comparative Bioavailability and Bioequivalence of Oxazepam 50 mg Orodispersible Tablets (Test) Versus Seresta® 50 mg Tablets (Reference): A Single-Dose, Open-Label, Randomized, Two-Sequence, Two-Treatment, Two-Period Crossover Study in Healthy Subjects	Portugal	Not Recruiting
Evaluation of Gastrointestinal Tolerability of Oral Tegomil Fumarate Versus Dimethyl Fumarate in Healthy Volunteers with Multiple Sclerosis	Portugal	Not Recruiting
Evaluation of the Efficacy and Safety of Extended-Release Levetiracetam as Adjunctive Therapy in Refractory Partial Onset Epilepsy: A Randomized, Double-Blind Study	Bulgaria Czechia Germany Greece Hungary Italy Poland Romania Spain	Recruiting